Jubilant Pharmova’s sterile injectable manufacturing arm commissions $132 million new line in U.S.
A fourth line is on the anvil amid growing demand from large innovator pharma companies for high quality, US manufacturing facilities in the wake of new tariffs imposed by the U.S. government, a top executive says
A fourth line is on the anvil amid growing demand from large innovator pharma companies for high quality, US manufacturing facilities in the wake of new tariffs imposed by the U.S. government, a top executive says
What's Your Reaction?
